{
    "root": "d360aaf2-0e56-4626-8bcf-7d480909a15a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Telisotuzumab Vedotin",
    "value": "20250514",
    "ingredients": [
        {
            "name": "TELISOTUZUMAB VEDOTIN",
            "code": "976X9VXC3Z",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15104"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_27570"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        }
    ],
    "indications": {
        "text": "emrelis indicated treatment adult patients locally advanced metastatic , non-squamous non-small cell lung cancer ( nsclc ) high c-met protein overexpression [ \u226550 % tumor cells strong ( 3+ ) staining ] , determined fda-approved test [ ( 2.1 ) ] , received prior systemic therapy . indication approved accelerated approval based overall response rate ( orr ) duration response ( dor ) [ ( 14 ) ] . continued approval indication may contingent upon verification description benefit confirmatory trial ( ) .",
        "doid_entities": [
            {
                "text": "non-small cell lung cancer (DOID:3908)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3908"
            },
            {
                "text": "lung cancer (DOID:1324)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1324"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "intravenous infusion . ( 2.5 ) recommended emrelis 1.9 mg/kg administered intravenously every 2 weeks disease progression unacceptable toxicity . ( 2.2 ) reconstitute dilute emrelis prior intravenous infusion . ( 2.5 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "supplied emrelis ( telisotuzumab vedotin-tllv ) injection sterile , preservative-free , white off-white lyophilized powder , supplied glass single-dose vial . carton one 20 mg/vial ( ndc 0074-1044-01 ) carton one 100 mg/vial ( ndc 0074-1055-01 ) storage handling store refrigerated 2oc 8oc ( 36of 46of ) original carton protect light . freeze . shake . special handling emrelis hazardous product . follow special handling disposal procedures.1",
    "adverseReactions": "none .",
    "indications_original": "EMRELIS is indicated for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high\u00a0c-Met protein overexpression\u00a0[\u226550% of tumor cells with strong (3+) staining], as determined by an FDA-approved test [see Dosage and Administration (\n                     \n                        2.1\n                     \n                     )], who have received a prior systemic therapy.\n                  \n                  This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response\u00a0(DOR) [see Clinical Studies (\n                     \n                        14\n                     \n                     )]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contraindications_original": "For intravenous infusion only. ( 2.5 ) The recommended dosage of EMRELIS\u00a0is 1.9 mg/kg administered intravenously every 2 weeks until disease progression or unacceptable toxicity. ( 2.2 ) Reconstitute and further dilute EMRELIS prior to intravenous infusion. ( 2.5 )",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  EMRELIS (telisotuzumab vedotin-tllv) for injection\u00a0is a sterile, preservative-free, white to off-white lyophilized powder, supplied in a glass single-dose vial.\n                  \n                     Carton of one 20\u00a0mg/vial\u00a0(NDC 0074-1044-01)\n                     \n                     Carton of one 100\u00a0mg/vial\u00a0(NDC 0074-1055-01)\n                  \n                  \n                     Storage and Handling\n                  \n                  Store refrigerated at 2oC\u00a0to\u00a08oC (36oF to\u00a046oF) in original carton to protect from light. Do not freeze. Do not shake.\n                  \n                     Special Handling\n                  \n                  EMRELIS\u00a0is a hazardous product. Follow special handling and disposal procedures.1",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "Telisotuzumab Vedotin",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15104"
        }
    ]
}